Skip to main content
Industry News
Gilead, Jounce seal $120M deal for cancer drug

Gilead Sciences has partnered with Jounce Therapeutics through a licensing deal for its cancer therapy drug, JTX-1811, with Jounce eligible for an upfront payment of $85 million plus a $35 million equity investment from Gilead. The deal could potentially bring in up to $685 million in milestone payments for Jounce.

Full Story: